Unconditioned Behavioral Effects of the Powerful κ-Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid
- 10 November 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 328 (2), 588-597
- https://doi.org/10.1124/jpet.108.145342
Abstract
Salvinorin A is the main active component of the widely available hallucinogenic plant, Salvia divinorum. Salvinorin A is a selective high-efficacy κ-agonist in vitro, with some unique pharmacodynamic properties. Descriptive reports show that salvinorin A-containing products produce robust behavioral effects in humans. However, these effects have not been systematically characterized in human or nonhuman primates to date. Therefore, the present studies focused on the characterization of overt effects of salvinorin A, such as sedation (operationally defined as unresponsiveness to environmental stimuli) and postural relaxation, previously observed with centrally penetrating κ-agonists in nonhuman primates. Salvinorin A was active in these endpoints (dose range, 0.01–0.1 mg/kg i.v.) in nonhuman primates (n = 3–5), similar to the synthetic κ-agonist U69,593 [(+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]-dec-8-yl]-benzeneacetamide], used for comparison herein. Salvinorin A effects could be prevented by a clinically available opioid antagonist, nalmefene (0.1 mg/kg), at doses known to block κ-receptor-mediated effects in nonhuman primates. When injected intravenously, salvinorin A (0.032 mg/kg) could enter the central nervous system (as reflected in cisternal cerebrospinal fluid) within 1 min and reach concentrations that are in the reported range of the affinity (Ki) of this ligand for brain κ-receptors. Consistent with this finding, specific translationally viable behavioral effects (e.g., facial relaxation and ptosis) could also be detected within 1 to 2 min of injection of salvinorin A. These are the first studies documenting rapid unconditioned effects of salvinorin A in a primate species, consistent with descriptive reports of rapid and robust effects of this powerful hallucinogen in humans.Keywords
This publication has 42 references indexed in Scilit:
- Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis‐induced hypermotility: cross‐talk between κ‐opioid and cannabinoid CB1 receptorsBritish Journal of Pharmacology, 2008
- College student use of Salvia divinorumDrug and Alcohol Dependence, 2008
- Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humansNeuroImage, 2008
- Discriminative Stimulus Effects of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane in Rhesus MonkeysJournal of Pharmacology and Experimental Therapeutics, 2007
- Stimulant medications: how to minimize their reinforcing effects?American Journal of Psychiatry, 2006
- Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primatesSynapse, 2005
- Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?Neuropsychopharmacology, 2005
- Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamicsAdvanced Drug Delivery Reviews, 2004
- Agonist-induced regulation and trafficking of $kappa; opioid receptorsLife Sciences, 2004
- Salvinorin A, an Active Component of the Hallucinogenic SageSalvia divinorumIs a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional ConsiderationsJournal of Pharmacology and Experimental Therapeutics, 2004